Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 4/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26244657 | 0.86 | MAOB (0.34) | HSP90AA1HSP90AB1TSHRMEN1KMT2A | |
| SCHEMBL21226532 | 0.83 | SLC22A12 (0.37) | TSHRMEN1KMT2A | |
| SCHEMBL26244650 | 0.81 | PDE7B (0.32) | — | |
| SCHEMBL26244648 | 0.74 | NOTUM (0.39) | TSHRCA12CA2CA3CA4 | |
| SCHEMBL26244636 | 0.71 | ESR1 (0.34) | CA12CA2CA3CA4CA6 | |
| SCHEMBL22336249 | 0.68 | ALDH1A1 (0.36) | TSHRMEN1KMT2A | |
| SCHEMBL23218741 | 0.66 | CHRM2 (0.48) | CA12CA2CA3CA4CA6 | |
| SCHEMBL26244601 | 0.66 | CHRM2 (0.51) | TSHRCA2MEN1KMT2A | |
| SCHEMBL26244652 | 0.66 | PDE7B (0.32) | — | |
| SCHEMBL21438786 | 0.66 | TSHR (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | HSP90AA1 3744/4885HSP90AB1 3437/4885CHKA 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.